Aileron Therapeutics to Present at Upcoming Scientific Conferences and Industry Events

CAMBRIDGE, Mass.--()--Aileron Therapeutics, Inc., a biopharmaceutical company developing and advancing a revolutionary class of drugs called Stapled Peptides, today announced the company’s participation in several upcoming scientific conferences and biotechnology industry events.

“This has been a very productive year for Aileron as we highlighted last week in our talk at The Seventh Peptide Therapeutics Symposium,” said Joseph A. Yanchik, III, president and chief executive officer of Aileron. “These upcoming forums provide an excellent opportunity to share additional updates across therapeutic areas on our Stapled Peptide drug programs as we prepare to enter the clinic early next year with our first-in-human Stapled Peptide.”

About Aileron Therapeutics

Aileron Therapeutics is creating the first new class of drugs in 20 years and is uniquely positioned to capitalize on key biological insights to attack complex diseases such as cancer, endocrine metabolic conditions and inflammation. By harnessing one of the most common, but elusive, structures in nature - the alpha helical peptide, we believe we can dramatically improve the treatment of these diseases and positively impact the lives of millions of patients around the globe. Aileron plans to initiate clinical development of its first Stapled Peptide drug in early 2013 with its wholly owned endocrine and metabolic disease program, ALRN-5281.

For more information, please visit www.aileronrx.com.

Contacts

Pure Communications, Inc.
Dan Budwick, 973-271-6085

Sharing

Contacts

Pure Communications, Inc.
Dan Budwick, 973-271-6085